FOI 5691 Breast cancer Treatment

Date: 11 November 2019 to 11 November 2022

Question 1a

               Does your trust treat advanced breast cancer ?

Question 1b

               If none, where are your patients referred?

Question 2

               In the past 3 months, how many advanced breast cancer patients [Stage IV] have the status of;            

HR+ and HER2+ [Hormone receptor-positive and human epidermal growth factor 2-positive]

 

HR+ and HER2- [Hormone receptor-positive and human epidermal growth factor 2-negative]

 

HR- and HER2+ [Hormone receptor-negative and human epidermal growth factor 2-positive]

 

HR- and HER2- [Hormone receptor-negative and human epidermal growth factor 2-negative] - Triple negative disease

 

Not Known

 

 

 

Question 3

               In the past 3 months, how many breast cancer patients were treated with:

Abemaciclib (Verzenios) + aromatase inhibitor * Abemaciclib (Verzenios) + Fulvestrant (Faslodex) Alpelisib (Piqray) + Fulvestrant (Faslodex) Atezolizumab (Tecentriq)** Bevacizumab (Avastin) Eribulin (Halaven) Everolimus (Afinitor) + Exemestane Fulvestrant (Faslodex) as a single agent Gemcitabine + paclitaxel Lapatinib (Tyverb) Neratinib (Nerlynx) Olaparib (Lynparza) Palbociclib (Ibrance) + aromatase inhibitor* Pertuzumab (Perjeta) + trastuzumab + docetaxel Ribociclib (Kisqali) + aromatase inhibitor* Ribociclib (Kisqali) + Fulvestrant (Faslodex) Talazoparib (Talzenna) Trastuzumab + paclitaxel Trastuzumab as a single agent Trastuzumab emtansine (Kadcyla)

Other active systemic anti-cancer therapy **

*aromatase inhibitor eg. Anastrozole, Exemestane or Letrozole **eg. docetaxel, vinorelbine or capecitabine as a single agent

  • Request ID:
    FOI 5691
  • Category:
    Patient - Activity Data
  • Response:

    Response attached